Table 2. Summary of patients with neutralizing activity against HIV-1JR-FL and/or HIV-2/HIV-1 7312-C1.
Patient ID # | IC50 * (μg/mL) | IC50? | |||
Virus | Virus | ||||
JR-FL | VSV-g | 7312-C1 | 7312-C1C | 7312A | |
9 | 34.1 | > 200 | < 100 | < 100 | < 100 |
10 | 56.0 | > 200 | < 100 | < 100 | < 100 |
11 | 125.0 | > 200 | < 100 | < 100 | < 100 |
12 | 42.9 | > 200 | 108 | < 100 | < 100 |
18 | 127.3 | > 200 | 116 | < 100 | < 100 |
26 | > 200 | > 200 | 109 | < 100 | < 100 |
32 | 65.5 | > 200 | < 100 | < 100 | < 100 |
35 | 41.5 | > 200 | < 100 | < 100 | < 100 |
41 | 38.7 | > 200 | < 100 | < 100 | < 100 |
42 | 17.5 | > 200 | < 100 | < 100 | < 100 |
48 | 3.0 | > 200 | 125 | < 100 | < 100 |
50 | 77.8 | > 200 | < 100 | < 100 | < 100 |
Polyclonal inhibitory concentration of purified IgG fractions
? Reciprocal dilution factor of serum samples